Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 20/20 | 0.71 |
| ▸ | SLC6A2 | P23975 | 16/20 | 0.71 |
| ▸ | SLC6A3 | Q01959 | 14/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23159342 | 1.00 | SLC6A4 (0.71) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL17071877 | 1.00 | SLC6A4 (0.71) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL17061994 | 1.00 | SLC6A4 (0.71) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL911325 | 0.93 | SLC6A4 (0.62) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL911347 | 0.93 | SLC6A4 (0.62) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL911326 | 0.93 | SLC6A4 (0.62) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL17061944 | 0.85 | SLC6A4 (0.58) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL17069398 | 0.85 | SLC6A4 (0.58) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL21825375 | 0.85 | SLC6A4 (0.58) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL18682213 | 0.85 | SLC6A4 (0.58) | SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210093618-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-04-01 | — | — | US | disclosed |
| US-20210093618-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-04-01 | — | — | US | disclosed |
| US-20200108054-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-04-09 | — | — | US | disclosed |
| US-9694002-B2 | Substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9694002-B2 | Substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9694002-B2 | Substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20170087136-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-03-30 | — | — | US | disclosed |
| US-20170087136-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-03-30 | — | — | US | disclosed |
| US-20170087136-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-03-30 | — | — | US | disclosed |
| US-9546164-B2 | Substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-9546164-B2 | Substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-20150252038-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | XENON PHARMACEUTICALS INC. (CA) | 2015-09-10 | — | — | US | disclosed |
| US-20150252038-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | XENON PHARMACEUTICALS INC. (CA) | 2015-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210093618-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, SULT2A1 | SLC6A4 1222/4885SLC6A2 1283/4885SLC6A3 1320/4885 |
| US-20150252038-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, RRM1 | SLC6A4 1432/4885SLC6A2 1679/4885SLC6A3 2186/4885 |
| US-20170087136-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | C1R, SRR, PNISR | SLC6A4 661/4885SLC6A2 927/4885SLC6A3 828/4885 |
| US-20200108054-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, SULT2A1 | SLC6A4 1222/4885SLC6A2 1283/4885SLC6A3 1320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.